×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Heart Pump Devices Market

ID: MRFR/HC/52752-HCR
200 Pages
Garvit Vyas
October 2025

UK Heart Pump Devices Market Research Report: Size, Share, Trend Analysis By Product (Ventricular Assist Devices, Left Ventricular Assist Devices, Right Ventricular Assist Devices, Bi- Ventricular Assist Devices, Percutaneous Ventricular Assist Devices, Transcutaneous Ventricular Assist Devices, Intra-Aortic Balloon Pumps, Total Artificial Heart), By Device Type (Implantable Heart Pump Devices, Extracorporeal Heart Pump Devices), By Therapy (Bridge-to-candidacy (BTC), Bridge-to-transplant (BTC), Destination Therapy (DT), Others) andBy End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Research Institutes, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Heart Pump Devices Market Infographic
Purchase Options

UK Heart Pump Devices Market Summary

As per Market Research Future analysis, the UK heart pump devices market size was estimated at 27.79 $ Million in 2024. The UK heart pump-devices market is projected to grow from 32.71 $ Million in 2025 to 166.74 $ Million by 2035, exhibiting a compound annual growth rate (CAGR) of 17.6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The UK heart pump devices market is poised for growth driven by technological advancements and increasing healthcare demands.

  • Technological advancements in heart pump devices are enhancing patient outcomes and operational efficiency.
  • The largest segment in the UK market is the ventricular assist devices (VADs), while the fastest-growing segment is expected to be the total artificial hearts.
  • Regulatory changes are shaping the landscape, promoting innovation and ensuring safety in device deployment.
  • The rising prevalence of cardiovascular diseases and government funding initiatives are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 27.79 (USD Million)
2035 Market Size 166.74 (USD Million)
CAGR (2025 - 2035) 17.69%

Major Players

Abbott (US), Medtronic (US), Boston Scientific (US), Terumo (JP), Cleveland Heart (US), CardiacAssist (US), Syncardia (US), Getinge (SE), LivaNova (GB)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

UK Heart Pump Devices Market Trends

The heart pump devices market is currently experiencing notable advancements driven by technological innovations and increasing demand for effective cardiac care solutions. The integration of artificial intelligence and machine learning into device functionality appears to enhance patient outcomes and streamline clinical workflows. Furthermore, the growing prevalence of cardiovascular diseases necessitates the development of more sophisticated heart pump devices, which may lead to improved patient management and reduced hospital readmission rates. As healthcare systems evolve, the focus on personalized medicine is likely to shape the future of this market, with devices tailored to individual patient needs becoming more commonplace. In addition, regulatory frameworks are adapting to accommodate the rapid pace of innovation within the heart pump-devices market. This shift may facilitate faster approvals for new technologies, thereby encouraging investment and research in this sector. The collaboration between manufacturers, healthcare providers, and regulatory bodies seems essential for fostering an environment conducive to innovation. As the market continues to expand, it is crucial for stakeholders to remain vigilant regarding emerging trends and potential challenges that may arise in the evolving landscape of cardiac care.

Technological Advancements

Recent innovations in heart pump devices are transforming treatment options. Enhanced features such as remote monitoring and data analytics are becoming standard, allowing for better patient management and outcomes. These advancements may lead to increased adoption rates among healthcare providers.

Regulatory Changes

The evolving regulatory landscape is likely to impact the heart pump-devices market significantly. Streamlined approval processes for new technologies may encourage manufacturers to invest in research and development, ultimately benefiting patients with more effective treatment options.

Focus on Personalized Medicine

There is a growing emphasis on personalized medicine within the heart pump-devices market. Tailoring devices to meet individual patient needs could enhance treatment efficacy and improve overall patient satisfaction, reflecting a shift towards more patient-centered care.

UK Heart Pump Devices Market Drivers

Growing Awareness and Patient Advocacy

The growing awareness of heart health and patient advocacy initiatives are driving factors in the heart pump-devices market. Public health campaigns aimed at educating individuals about cardiovascular health have gained momentum in the UK, leading to increased screening and early diagnosis of heart conditions. This heightened awareness encourages patients to seek advanced treatment options, including heart pump devices, as viable solutions for managing their health. Furthermore, patient advocacy groups are actively promoting the benefits of these devices, influencing public perception and acceptance. As more patients become informed about their treatment options, the demand for heart pump devices is likely to rise, thereby contributing to market growth. This trend underscores the importance of education and advocacy in shaping healthcare choices.

Government Funding and Support Initiatives

Government funding and support initiatives play a crucial role in shaping the heart pump-devices market. The UK government has been actively promoting research and development in medical technologies, including heart pump devices, through various funding programs. For example, the National Institute for Health Research (NIHR) has allocated substantial resources to support clinical trials and innovation in cardiovascular treatments. This financial backing encourages manufacturers to invest in new technologies and improve existing products, thereby enhancing the overall market landscape. Additionally, the government's focus on improving healthcare access and outcomes may lead to increased adoption of heart pump devices in clinical settings. Consequently, the heart pump-devices market is likely to benefit from sustained government support and investment.

Technological Innovations in Device Design

Innovations in the design and functionality of heart pump devices are significantly influencing the heart pump-devices market. Recent advancements include the development of miniaturized pumps and improved biocompatible materials, which enhance device performance and patient comfort. For instance, the introduction of wearable heart pumps has the potential to revolutionize treatment protocols, allowing for greater mobility and quality of life for patients. The UK has seen a surge in research and development initiatives aimed at creating more efficient and durable devices. This focus on innovation not only addresses the clinical needs of patients but also aligns with the NHS's commitment to adopting cutting-edge technologies. As a result, the heart pump-devices market is expected to expand as these innovations gain traction among healthcare providers.

Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases in the UK is a primary driver for the heart pump-devices market. According to recent health statistics, cardiovascular diseases account for approximately 27% of all deaths in the UK, highlighting a critical public health issue. This alarming trend necessitates advanced medical interventions, including heart pump devices, to manage heart failure and other related conditions. As the population ages, the demand for effective treatment options is likely to escalate, propelling market growth. Furthermore, the National Health Service (NHS) has been investing in innovative technologies to improve patient outcomes, which may further stimulate the heart pump-devices market. The combination of rising disease prevalence and healthcare investments suggests a robust market trajectory in the coming years.

Aging Population and Increased Healthcare Demand

The aging population in the UK is a significant driver of the heart pump-devices market. As life expectancy continues to rise, the prevalence of age-related cardiovascular conditions is expected to increase correspondingly. Older adults are more susceptible to heart diseases, necessitating advanced medical interventions such as heart pump devices. The Office for National Statistics (ONS) projects that by 2040, the number of individuals aged 65 and over will reach approximately 20 million, further intensifying the demand for effective cardiovascular treatments. This demographic shift is prompting healthcare providers to seek innovative solutions to manage heart failure and other related conditions. Consequently, the heart pump-devices market is poised for growth as healthcare systems adapt to meet the needs of an aging population.

Market Segment Insights

By Product: Left Ventricular Assist Devices (Largest) vs. Right Ventricular Assist Devices (Fastest-Growing)

Among the various product segments in the UK heart pump-devices market, left ventricular assist devices (LVADs) hold the largest market share. These devices are primarily used for patients with severe heart failure, providing crucial support for left ventricular function. Conversely, right ventricular assist devices (RVADs) are gaining traction and are noted as the fastest-growing segment, driven by an increasing patient population requiring right ventricular support. The growth trends in this segment are primarily influenced by advancements in technology and rising incidences of heart diseases, prompting healthcare providers to adopt innovative solutions. Additionally, an increasing number of clinical trials for RVADs is likely to enhance their adoption and efficacy. As healthcare infrastructures evolve, both LVADs and RVADs are expected to solidify their presence in the market, catering to the diverse needs of patients with failing heart functions.

Left Ventricular Assist Devices (Dominant) vs. Right Ventricular Assist Devices (Emerging)

Left ventricular assist devices (LVADs) have established themselves as the dominant force in the UK heart pump-devices market, playing a critical role in the management of advanced heart failure. These devices are designed to significantly improve the quality and duration of life for patients awaiting heart transplants or those who are ineligible for surgery. Conversely, right ventricular assist devices (RVADs) are emerging as vital alternatives, especially in acute care settings where right ventricular support is necessary due to various cardiac conditions. The innovative designs and growing clinical validation of RVADs reflect a changing landscape in heart pump technology. Thus, while LVADs maintain a stronghold, RVADs are expanding their footprint, showcasing the dynamic evolution within the heart pump device sector.

By Device Type: Implantable heart pump devices (Largest) vs. Extracorporeal heart pump devices (Fastest-Growing)

The UK heart pump-devices market showcases a distinctive distribution of market share between implantable and extracorporeal heart pump devices. Implantable heart pump devices hold a substantial share, capitalizing on the growing demand for long-term cardiac support solutions. In contrast, extracorporeal heart pump devices are garnering increased attention, particularly in emergency settings, highlighting a shift in clinical preferences. Growth trends in this segment reveal a rising inclination towards minimally invasive procedures, which favor implantable devices due to their advanced technology and durability. Meanwhile, the emergence of extracorporeal devices as the fastest-growing category is driven by innovations that enhance their effectiveness in acute situations, positioning them as vital tools in critical care management.

Implantable heart pump devices (Dominant) vs. Extracorporeal heart pump devices (Emerging)

Implantable heart pump devices are established as the dominant category within the UK heart pump-devices market, driven by their effectiveness in managing chronic heart failure and offering patients a better quality of life. This segment benefits from extensive clinical endorsement and ongoing technological advancements that improve device performance and patient outcomes. On the other hand, extracorporeal heart pump devices, although currently emerging, are gaining traction due to their ability to provide rapid circulatory support in urgent medical situations. This growth is fueled by advancements in device engineering and an increasing focus on patient outcomes during critical interventions, establishing a complementary role alongside implantable devices.

By Therapy: Bridge-to-transplant (Largest) vs. Destination therapy (Fastest-Growing)

In the UK heart pump-devices market, the market share distribution indicates that Bridge-to-transplant (BTC) holds the largest share, reflecting its critical role in managing patients awaiting heart transplants. This segment has solidified its importance in the therapeutic landscape, while other segments like Bridge-to-candidacy and Destination therapy are also making substantial contributions, showcasing the diversity and specialization within treatment options. Examining growth trends, Destination therapy (DT) is recognized as the fastest-growing segment, driven by technological advancements and increasing patient awareness of long-term therapy options. Factors such as an aging population, rising prevalence of heart failure, and the need for durable solutions boost the demand for these innovative therapeutic approaches, enhancing the overall market dynamics.

Bridge-to-transplant (Dominant) vs. Destination therapy (Emerging)

Bridge-to-transplant (BTC) is considered the dominant therapy in the UK heart pump-devices market. This segment provides a temporary solution for patients waiting for heart transplants, ensuring they receive necessary support while awaiting a donor organ. Its established presence is coupled with a high demand for effective, life-saving therapies. On the other hand, Destination therapy (DT) is emerging rapidly, appealing to patients not eligible for transplant. It offers long-term support and reflects a shift towards more sustainable healthcare solutions. Both segments play integral roles in addressing heart failure, but BTC remains critical as the leading choice among clinicians for urgent intervention, while DT represents a promising future with advancements in technology.

By End-User: Hospitals & Clinics (Largest) vs. Research Institutes (Fastest-Growing)

The market share distribution among the key end-user segments in the UK heart pump-devices market reveals that Hospitals & Clinics continue to hold the largest share, significantly outpacing other segments like Ambulatory Surgical Centers and Research Institutes. These facilities account for a substantial portion of the demand due to their comprehensive cardiac care services and advanced treatment capabilities, which are critical in addressing various heart conditions. Meanwhile, the 'Others' segment maintains a smaller yet essential role, contributing to niche applications in cardiac support and management. Growth trends indicate that Research Institutes are emerging as the fastest-growing segment, driven by increased investment in cardiac research and innovation. As more clinical trials focus on novel heart pump technologies and techniques, these institutions are progressively becoming hubs for groundbreaking advancements. Additionally, the rising prevalence of heart diseases among the population amplifies the need for effective treatments, further fueling demand across all segments, particularly in specialized research settings.

Hospitals & Clinics (Dominant) vs. Research Institutes (Emerging)

Hospitals & Clinics represent the dominant force in the UK heart pump-devices market due to their extensive resources and capacity to implement advanced cardiac treatment solutions. These facilities are equipped with the latest technologies, enabling them to offer comprehensive heart care services, which are paramount in managing chronic heart conditions. On the other hand, Research Institutes are classified as an emerging segment, playing a pivotal role in fostering innovation within the market. Their focus on research initiatives and partnerships with medical device manufacturers drives the development of next-generation heart pump technologies. By harnessing academic expertise and clinical insights, these institutes are set to shape future trends and propel the market forward, establishing themselves as key players in the evolving landscape of cardiac care.

Get more detailed insights about UK Heart Pump Devices Market

Key Players and Competitive Insights

The heart pump-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of cardiovascular diseases. Key players such as Abbott (US), Medtronic (US), and Boston Scientific (US) are at the forefront, focusing on innovation and strategic partnerships to enhance their market positions. Abbott (US) emphasizes the development of minimally invasive devices, while Medtronic (US) is known for its robust pipeline of heart pump technologies. Boston Scientific (US) is actively pursuing collaborations to expand its product offerings, thereby shaping a competitive environment that prioritizes cutting-edge solutions and patient-centric approaches.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Terumo (JP) and LivaNova (GB) is notable, as they leverage their global reach and technological expertise to enhance their competitive edge.

In October Medtronic (US) announced a strategic partnership with a leading AI firm to integrate artificial intelligence into its heart pump devices. This move is likely to enhance device performance and patient monitoring capabilities, reflecting a broader trend towards digital transformation in the healthcare sector. The integration of AI could potentially lead to improved patient outcomes and operational efficiencies, positioning Medtronic (US) as a leader in innovation.

In September Abbott (US) launched a new line of heart pump devices designed for patients with advanced heart failure. This product introduction is significant as it addresses a growing need for effective treatment options in this patient population. By expanding its product portfolio, Abbott (US) aims to capture a larger market share and reinforce its commitment to improving patient care.

In August Boston Scientific (US) entered into a collaboration with a prominent research institution to develop next-generation heart pump technologies. This partnership is indicative of the company's strategy to leverage external expertise and accelerate innovation. Such collaborations may enhance Boston Scientific's ability to bring novel solutions to market, thereby strengthening its competitive position.

As of November current trends in the heart pump-devices market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of developing cutting-edge solutions that meet the evolving needs of patients and healthcare providers.

Key Companies in the UK Heart Pump Devices Market include

Industry Developments

The UK Heart Pump Devices Market has seen significant advancements recently, particularly in the technologies developed by companies like Medtronic and Abbott Laboratories. In August 2023, LivaNova announced the launch of an innovative heart pump device, enhancing options for patients with advanced heart failure.

Meanwhile, Terumo Corporation continues to expand its product offerings, aiming to meet the increasing demand for minimally invasive procedures. In terms of mergers and acquisitions, Boston Scientific completed the acquisition of a cardiac device division from Edwards Lifesciences in July 2023, aligning with the growing trend of consolidation in the medical device sector.

This acquisition is expected to enhance Boston Scientific’s portfolio in the heart pump segment. Additionally, the market is experiencing steady growth, as evidenced by the increased revenue reported by Abiomed in the first quarter of 2023, attributed to its technological innovations in heart pump therapy.

Notably, the UK’s National Health Service has also been investing in improving healthcare infrastructure, which is creating a favorable environment for heart pump device manufacturers. Over the past few years, the market has undergone rigorous developments, positioning the UK as a key player in the European heart pump device landscape.

Future Outlook

UK Heart Pump Devices Market Future Outlook

The Heart Pump Devices Market is projected to grow at a 17.69% CAGR from 2025 to 2035, driven by technological advancements, increasing cardiovascular diseases, and rising healthcare expenditure.

New opportunities lie in:

  • Development of portable heart pump devices for home care settings.
  • Investment in AI-driven predictive analytics for patient monitoring.
  • Expansion of telehealth services integrating heart pump management.

By 2035, the heart pump-devices market is expected to achieve substantial growth and innovation.

Market Segmentation

UK Heart Pump Devices Market Product Outlook

  • Ventricular assist devices
  • Left ventricular assist devices
  • Right ventricular assist devices
  • Bi-ventricular assist devices
  • Percutaneous ventricular assist devices
  • Transcutaneous ventricular assist devices
  • Intra-Aortic balloon pumps
  • Total artificial heart

UK Heart Pump Devices Market Therapy Outlook

  • Bridge-to-candidacy (BTC)
  • Bridge-to-transplant (BTC)
  • Destination therapy (DT)
  • Others

UK Heart Pump Devices Market End-User Outlook

  • Hospitals & Clinics
  • Ambulatory surgical centers
  • Research institutes
  • Others

UK Heart Pump Devices Market Device Type Outlook

  • Implantable heart pump devices
  • Extracorporeal heart pump devices

Report Scope

MARKET SIZE 2024 27.79(USD Million)
MARKET SIZE 2025 32.71(USD Million)
MARKET SIZE 2035 166.74(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 17.69% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Abbott (US), Medtronic (US), Boston Scientific (US), Terumo (JP), Cleveland Heart (US), CardiacAssist (US), Syncardia (US), Getinge (SE), LivaNova (GB)
Segments Covered Product, Device Type, Therapy, End-User
Key Market Opportunities Advancements in minimally invasive heart pump technologies enhance patient outcomes and market potential.
Key Market Dynamics Technological advancements and regulatory changes drive innovation in the heart pump-devices market, enhancing patient outcomes.
Countries Covered UK
Leave a Comment

FAQs

What is the expected market value of the UK Heart Pump Devices Market in 2024?

The UK Heart Pump Devices Market is expected to be valued at 37.0 USD Million in 2024.

What will be the value of the UK Heart Pump Devices Market by 2035?

By 2035, the overall value of the UK Heart Pump Devices Market is projected to reach 185.0 USD Million.

What is the expected compound annual growth rate (CAGR) for the UK Heart Pump Devices Market from 2025 to 2035?

The expected CAGR for the UK Heart Pump Devices Market from 2025 to 2035 is 15.756%.

Which product segment is the largest in the UK Heart Pump Devices Market?

The Left Ventricular Assist Devices segment is growing significantly and is expected to be one of the largest in the UK market.

How much is the Ventricular Assist Devices segment valued at in 2024?

The Ventricular Assist Devices segment is valued at 8.0 USD Million in 2024.

What is the projected market size for the Right Ventricular Assist Devices by 2035?

The Right Ventricular Assist Devices market is projected to reach 30.0 USD Million by 2035.

Who are the key players in the UK Heart Pump Devices Market?

Major players in the UK Heart Pump Devices Market include Medtronic, Abbott Laboratories, and LivaNova among others.

What challenges might the UK Heart Pump Devices Market face in the coming years?

The market could face challenges such as regulatory hurdles and the need for technological advancements.

What market opportunities exist for Heart Pump Devices in the UK?

Opportunities include rising demand for heart failure treatments and advancements in device technology.

What will the market value be for Bi-Ventricular Assist Devices by 2035?

The Bi-Ventricular Assist Devices segment is expected to grow to 25.0 USD Million by 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions